SCHEMBL716475

SCHEMBL716475

Cc1cccc2cc([C@H](C)N)c(N3CCNC(=O)C3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 5/20 0.40
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 3/20 0.38
USP2 O75604 1/20 0.38
CLK1 P49759 1/20 0.38
PRKCH P24723 1/20 0.38
PRKCE Q02156 1/20 0.38
SOS1 Q07889 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
OPRM1 P35372 2/20 0.36
OPRK1 P41145 2/20 0.36
OGFRL1 Q5TC84 2/20 0.36
OPRD1 P41143 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11674 0.88 PRKCH (0.37) PIK3CDKDM4EALDH1A1PRKCHPRKCE
SCHEMBL714565 0.88 PRKCH (0.37) KDM4EALDH1A1PRKCHPRKCESOS1
SCHEMBL11673 0.88 PRKCH (0.37) PIK3CDKDM4EALDH1A1PRKCHPRKCE
SCHEMBL714566 0.88 PRKCH (0.37) KDM4EALDH1A1PRKCHPRKCESOS1
SCHEMBL14480684 0.83 SOS1 (0.37) KDM4EPRKCHPRKCESOS1OPRM1
SCHEMBL14480681 0.83 SOS1 (0.37) KDM4EPRKCHPRKCESOS1OPRM1
SCHEMBL717871 0.82 PRKCH (0.38) KDM4EPRKCHPRKCESOS1OPRM1
SCHEMBL717872 0.82 PRKCH (0.38) KDM4EPRKCHPRKCESOS1OPRM1
SCHEMBL716805 0.82 PIK3CD (0.40) PIK3CDTSHRALOX15CASP1CASP7
SCHEMBL716764 0.81 PIK3CD (0.48) PIK3CDTSHRALOX15CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885TSHR 931/4885ALOX15 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.